Steven Feldman to Off-Label Use
This is a "connection" page, showing publications Steven Feldman has written about Off-Label Use.
Connection Strength
0.947
-
Parikh SA, Davis SA, Krowchuk DP, Feldman SR. Common use of prescription off-label acne therapy in children younger than 12 years old. Pediatr Dermatol. 2014 Sep-Oct; 31(5):551-5.
Score: 0.478
-
Cline A, McGregor SP, Feldman SR. Medical Management of Facial Redness in Rosacea. Dermatol Clin. 2018 Apr; 36(2):151-159.
Score: 0.152
-
Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. J Manag Care Spec Pharm. 2017 May; 23(5):583-589.
Score: 0.146
-
Dunn LK, Gaar LR, Yentzer BA, O'Neill JL, Feldman SR. Acitretin in dermatology: a review. J Drugs Dermatol. 2011 Jul; 10(7):772-82.
Score: 0.097
-
Freeze ME, Balogh EA, Cline A, Feldman SR, Fleischer AB. Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age. Pediatr Dermatol. 2021 Jan; 38(1):115-118.
Score: 0.047
-
Davis SA, Sandoval LF, Gustafson CJ, Feldman SR, Cordoro KM. Treatment of preadolescent acne in the United States: an analysis of nationally representative data. Pediatr Dermatol. 2013 Nov-Dec; 30(6):689-94.
Score: 0.028